Home » Stocks » Plus Therapeutics

Plus Therapeutics, Inc. (PSTV)

Stock Price: $2.65 USD -0.03 (-1.12%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 12.17M
Revenue (ttm) 6.26M
Net Income (ttm) -1.52M
Shares Out 4.59M
EPS (ttm) -30.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $2.65
Previous Close $2.68
Change ($) -0.03
Change (%) -1.12%
Day's Open 2.70
Day's Range 2.57 - 2.70
Day's Volume 117,923
52-Week Range 0.93 - 3.56

More Stats

Market Cap 12.17M
Enterprise Value 9.66M
Earnings Date (est) Oct 22, 2020
Ex-Dividend Date n/a
Shares Outstanding 4.59M
Float 4.30M
EPS (basic) 13.72
EPS (diluted) -30.62
FCF / Share -1.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 380,539
Short Ratio 0.17
Short % of Float 8.86%
Beta 0.49
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.94
PB Ratio 3.73
Revenue 6.26M
Operating Income -4.33M
Net Income -1.52M
Free Cash Flow -4.08M
Net Cash 2.51M
Net Cash / Share 0.55
Gross Margin 26.08%
Operating Margin -69.08%
Profit Margin -33.10%
FCF Margin -65.11%
ROA -19.44%
ROE -96.70%
ROIC -6.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.50*
(107.55% upside)
Low
5.00
Current: $2.65
High
6.00
Target: 5.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue7.002.986.4111.3811.667.6012.2014.5010.0010.63
Revenue Growth134.6%-53.47%-43.66%-2.39%53.45%-37.7%-15.9%45.07%-5.94%-
Gross Profit7.002.985.099.218.474.668.7810.506.166.72
Operating Income-3.66-8.76-19.46-19.16-22.95-32.81-33.35-28.29-33.03-26.58
Net Income-10.89-12.63-22.69-22.05-18.74-37.37-26.18-32.28-32.45-27.49
Shares Outstanding1.380.170.060.030.020.010.010.010.010.01
Earnings Per Share-8.27-86.98-411.50-640.00-1,035.00-3,598.20-2,923.54-4,122.94-4,572.71-4,497.75
Operating Cash Flow-5.91-11.98-18.13-19.53-20.47-30.33-34.56-32.19-35.32-23.57
Capital Expenditures-0.07-0.13-0.180.06-0.60-0.694.48-1.20-0.56-0.61
Free Cash Flow-5.97-12.11-18.31-19.47-21.07-31.02-30.08-33.40-35.88-24.18
Cash & Equivalents17.595.3010.2312.9114.6914.9715.8626.0737.2753.02
Total Debt11.8514.2013.6217.6416.6825.4026.2922.6924.4519.71
Net Cash / Debt5.74-8.90-3.40-4.73-1.99-10.43-10.443.3812.8233.31
Assets23.2323.9931.6234.6137.7038.7242.0643.2551.5366.35
Liabilities22.0718.7718.6223.6225.4944.4238.9336.8041.5943.47
Book Value1.165.2313.0010.9912.21-5.703.136.469.9522.87
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Plus Therapeutics, Inc.
Country United States
Employees 12
CEO Marc H. Hedrick

Stock Information

Ticker Symbol PSTV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PSTV

Description

Plus Therapeutics, a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.